Gilead Urged to Cut Virus Drug’s Price if It Fails to Save Lives

Gilead Sciences Inc. should be prepared to dramatically slash the price of its Covid-19 drug remdesivir if the drug fails to reduce deaths, an organization that analyzes the value of health-care treatments says.

Gilead has priced remdesivir at an estimated $3,120 for commercial health insurers. But so far the drug, which the Trump administration said Monday it was buying for U.S. hospitals, has not proved to significantly reduce deaths from Covid-19, although it does help people feel better faster, Steven Pearson, founder and president of the Institute for Clinical and Economic Review, said in an interview.

If the drug doesn’t ...